Achaogen Inc. (NASDAQ:AKAO) was up 4.7% during trading on Wednesday . The company traded as high as $4.00 and last traded at $3.99, with a volume of 95,784 shares changing hands. The stock had previously closed at $3.81.

A number of research analysts recently weighed in on AKAO shares. Zacks Investment Research upgraded Achaogen from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Wednesday, July 6th. Needham & Company LLC reiterated a “hold” rating on shares of Achaogen in a report on Monday, May 9th. Cowen and Company cut Achaogen from an “outperform” rating to a “market perform” rating in a report on Thursday, March 31st. Finally, Wedbush reiterated a “neutral” rating and issued a $7.00 target price on shares of Achaogen in a report on Friday, May 6th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $10.63.

The company’s market cap is $72.71 million. The company has a 50-day moving average price of $3.96 and a 200 day moving average price of $3.63.

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.